The ADORA3 antibody targets the adenosine A3 receptor (ADORA3), a G protein-coupled receptor (GPCR) that binds adenosine to mediate diverse physiological responses. ADORA3 is primarily expressed in immune cells (e.g., mast cells, neutrophils), the central nervous system, and cardiovascular tissues. It plays roles in modulating inflammation, cell proliferation, and apoptosis, making it a focus in cancer, ischemic conditions, and autoimmune diseases. ADORA3 activation can either promote or inhibit tumor growth depending on the context, highlighting its dual role in oncology. Antibodies against ADORA3 are critical tools for detecting receptor expression, localization, and function in research. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to study ADORA3's involvement in signaling pathways (e.g., cAMP inhibition, MAPK activation). Challenges in developing ADORA3 antibodies include its low endogenous expression and high homology with other adenosine receptors, necessitating rigorous validation for specificity. Recent studies explore ADORA3 as a therapeutic target, with selective agonists/antagonists in clinical trials for conditions like rheumatoid arthritis, glaucoma, and liver fibrosis. Reliable ADORA3 antibodies thus support both mechanistic research and drug development, bridging insights into receptor biology and translational applications.